-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $17

Benzinga·11/17/2026 16:00:09
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $16 to $17.